Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday

Published 17/04/2024, 07:06
© Reuters.  Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
TRV
-
ABT
-
USB
-
OTRK
-
ITCI
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Wall Street expects Abbott Laboratories (NYSE: ABT) to report quarterly earnings at 95 cents per share on revenue of $9.88 billion before the opening bell, according to data from Benzinga Pro. Abbott shares gained 1% to $110.30 in after-hours trading.

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) disclosed a $500 million proposed public offering of common stock. Intra-Cellular Therapies shares fell 1.3% to $78.80 in the after-hours trading session.

Analysts are expecting U.S. Bancorp (NYSE: USB) to post quarterly earnings at 88 cents per share on revenue of $6.72 billion. The company will release earnings before the markets open. U.S. Bancorp shares fell 0.6% to $40.75 in after-hours trading.

Check out our premarket coverage here

Ontrak, Inc. (NASDAQ: OTRK) reported worse-than-expected fourth-quarter financial results. The company posted adjusted loss of 27 cents per share, compared to market expectations for a loss of 21 cents per share. The company's quarterly sales came in at $3.539 million, missing estimates of $4.037 million. Ontrak shares fell 14.2% to $0.3949 in the after-hours trading session.

Analysts expect The Travelers Companies, Inc. (NYSE: TRV) to post quarterly earnings at $4.90 per share on revenue of $10.51 billion before the opening bell. Travelers shares gained 0.8% to $224.98 in after-hours trading.

Check This Out: Top 4 Tech Stocks You May Want To Dump In April

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.